Market Overview:
The gastritis treatment market mainly comprises drugs belonging to the classes Proton Pump Inhibitors (PPIs), H2 Receptor Antagonists (H2RAs), Antacids and so on. PPIs and H2RAs are commonly prescribed as the first line of treatment to reduce stomach acid and relieve symptoms of gastritis.
The global Gastritis Treatment Market is estimated to be valued at US$ 131.76 Bn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period from 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the gastritis treatment market is the rising adoption of PPIs. PPIs act by irreversibly blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the proton pump) of gastric parietal cells and thereby provide effective and long-lasting relief from gastric acid related diseases like gastritis. PPIs are generally more effective than H2RAs in treating gastritis due to their ability to produce a sustained reduction in gastric acid secretion. Moreover, PPIs have minimal effects on nutrient absorption.
Segment Analysis
The gastritis treatment market can be segmented into acute gastritis and chronic gastritis. Chronic gastritis is currently dominating the market as it is the most common type of gastritis. Chronic gastritis develops gradually over several years and causes long-term damage to the stomach lining. It is often caused by H. pylori infection or long-term use of NSAIDs.
Key Takeaways
The global gastritis treatment market is expected to witness high growth, exhibiting CAGR of 6.2% over the forecast period, due to increasing prevalence of H. pylori infections and peptic ulcer disease.
Regional analysis - Asia Pacific region is expected to grow the fastest in the gastritis treatment market during the forecast period. This is attributed to the rising healthcare expenditure and presence of a large patient pool in countries like India and China. North America currently dominates the market due to growing awareness regarding gastric diseases and availability of advanced treatment options.
Key players - Key players operating in the gastritis treatment market are Pfizer Inc., AstraZeneca plc, Johnson & Johnson, Novartis AG, Takeda Pharmaceutical Company Limited. These players are focusing on new product launches and geographic expansion to gain market share and cater to the needs of more patients suffering from gastric diseases.
No comments:
Post a Comment